301 related articles for article (PubMed ID: 14964344)
21. Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis.
Betanzos-Cabrera G; Juárez-Verdayes MA; González-González G; Cancino-Díaz ME; Cancino-Díaz JC
Ophthalmic Res; 2009; 42(1):43-8. PubMed ID: 19478540
[TBL] [Abstract][Full Text] [Related]
22. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Mather R; Karenchak LM; Romanowski EG; Kowalski RP
Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779
[TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Wenzler S; Schmidt-Eisenlohr E; Daschner F
Chemotherapy; 2004 Apr; 50(1):40-2. PubMed ID: 15084805
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
25. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
Ozdek SC; Miller D; Flynn PM; Flynn HW
Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of fluoroquinolones against common respiratory pathogens.
Aydemir S; Tunger A; Cilli F
West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
[TBL] [Abstract][Full Text] [Related]
28. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Hedlin P; Blondeau JM
Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of bacterial keratitis at a tertiary eye care centre in India.
Kaliamurthy J; Kalavathy CM; Parmar P; Nelson Jesudasan CA; Thomas PA
Biomed Res Int; 2013; 2013():181564. PubMed ID: 24066286
[TBL] [Abstract][Full Text] [Related]
30. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
Kim DH; Stark WJ; O'Brien TP; Dick JD
Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
Hoogkamp-Korstanje JA; Roelofs-Willemse J
J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Naber KG; Hollauer K; Kirchbauer D; Witte W
Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
[TBL] [Abstract][Full Text] [Related]
33. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Segreti J; Jones RN; Bertino JS
J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
[TBL] [Abstract][Full Text] [Related]
35. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Park SH; Lim JA; Choi JS; Kim KA; Joo CK
Cornea; 2009 Jan; 28(1):68-72. PubMed ID: 19092409
[TBL] [Abstract][Full Text] [Related]
36. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
[TBL] [Abstract][Full Text] [Related]
37. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Fintelmann RE; Hoskins EN; Lietman TM; Keenan JD; Gaynor BD; Cevallos V; Acharya NR
Arch Ophthalmol; 2011 Apr; 129(4):399-402. PubMed ID: 21482865
[TBL] [Abstract][Full Text] [Related]
38. In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.
Kowalski RP; Kowalski TA; Shanks RM; Romanowski EG; Karenchak LM; Mah FS
Cornea; 2013 Jun; 32(6):830-4. PubMed ID: 23132444
[TBL] [Abstract][Full Text] [Related]
39. Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
Suzuki T; Ohashi Y
Cornea; 2013 Jul; 32(7):e156-60. PubMed ID: 23665643
[TBL] [Abstract][Full Text] [Related]
40. The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva.
Pettey JH; Mifflin MD; Kamae K; McEntire MW; Pettey DH; Callegan MC; Brown H; Olson RJ
J Ocul Pharmacol Ther; 2013 Jun; 29(5):450-5. PubMed ID: 23425429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]